Researchers use synthetic biology approaches to test hundreds of DNA sequences for their effect on regulating gene expression

Researchers from Heidelberg University’s Faculty of Medicine, Harvard Medical School, and the German Cancer Research Center (DKFZ) have uncovered key mechanisms underlying the proliferation of the malaria parasite Plasmodium. The molecular processes that govern the formation of infectious daughter parasites and new nuclei are essential for parasite survival and may therefore represent targets for future antimalarial therapies.

The University of Freiburg took part in this year’s Käpsele Innovation Festival with contributions from the fields of research and entrepreneurship promotion. The event focused on future-oriented topics such as Artificial Intelligence, cybersecurity and resilience, as well as on fostering dialogue and networking amongst stakeholders from the worlds of academia, business and politics.

EMUNO Therapeutics: the innate immune system as a new approach to cancer treatment - 29/07/2026

Activation of macrophages: a key factor in the fight against colorectal cancer

The mobilisation of the body’s own immune system through immune checkpoint inhibitors has revolutionised cancer therapy. However, the majority of solid tumours are able to evade immune surveillance. These so-called 'cold' tumours contain too few immune cells to respond effectively to current immunotherapies. This is where the Freiburg-based biotech start-up EMUNO Therapeutics GmbH comes in.

Most everyday moments are quickly forgotten, while others stay with us for a lifetime. How the brain determines which memories are retained and which are lost remains an open question. A neuroscience team at the University of Tübingen, has found that spontaneous fluctuations in the brain’s internal state influence how ready the memory system is to store new information.

On July 24, 2026, the Medical Center – University of Freiburg, the University of Freiburg, and the medical technology company Siemens Healthineers opened their joint Technology Innovation Lab, for short. In the lab at the Department of Radiation Oncology, experts in medicine, medical physics, radiation biology, and data science are working together with engineers to develop and test new technologies for radiation therapy to treat cancer.

A team of researchers from the Heidelberg Institute for Theoretical Studies and the Max Planck Institute for Polymer Research have developed a model that learns how to generate proteins whose structures are highly flexible, even with patterns that are uncommon in natural proteins. Their work, marks a step towards the goal of designing new proteins for applications in biotechnology, therapeutics and environmental research.

BioM Biotech Cluster Development GmbH, bioRN Life Science Cluster and ESMT Berlin announced the establishment of a Unified Hub for Healthcare Innovation. Through this alliance, the two biotech cluster organizations and DEEP – Institute for Deep Tech Innovation at ESMT will collaborate strategically to reinforce Germany’s position as a leading hub for translating scientific breakthroughs into impactful healthcare solutions.

Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development.

It has long been suspected that endothelial cells play a key role in determining how the body’s immune system responds to tumors. Researchers at the DKFZ and the Medical Faculty Mannheim of Heidelberg University have now identified, in mouse studies, a specialized population of blood vessel lining endothelial cells that enable an effective immune defense against cancer metastases in the liver.

Researchers have designed synthetic and inducible proteins that bind to bright fluorescent dyes with high specificity and affinity, significantly expanding the toolkit for multicolour imaging of proteins inside cells.

Researchers at the NCT Heidelberg and the German Cancer Research Center (DKFZ) have, for the first time, systematically determined how specific mutations promote acute myeloid leukemias. The results show why IDH1- and IDH2-mutated leukemias develop differently despite similar molecular mechanisms—and open up new approaches for diagnostics and targeted therapies.

Being overweight and obesity may contribute to significantly more cancer cases than previously thought. This is the conclusion reached by researchers at the German Cancer Research Center (DKFZ). Their analysis shows that when more accurate measures of body fat and methodological biases are considered, more than 10 percent of all cancer cases can be attributed to increased body weight - nearly twice as many as previous estimates suggested.

CRISPR base editing for tailored tumour treatment - 16/07/2026

Targeted genetic manipulation of signal transduction pathways in CAR T cells enhances anti-tumour potency

Chimeric antigen receptor (CAR) T cell therapy has emerged as a highly promising treatment modality but has so far been used almost exclusively for advanced haematologic malignancies. Researchers at the iFIT cluster of excellence in Tübingen have now used CRISPR base-editing technology to introduce precise point mutations into key signalling pathways of CAR T cells, significantly enhancing their long-term persistence and anti-tumour potency.

With the aid of physical forces it is possible to actively steer the formation of engineered tissue. For example, sound waves can be used to create functional vascular networks with blood vessel-like structures in vitro. Scientists at the Center for Molecular Biology of Heidelberg University have demonstrated this through their methodology for acoustic manipulation.

The University of Hohenheim becomes a European University through the EuroLeague of Life Sciences Universities. For ELLS, which is celebrating its 25th anniversary this year, this marks the beginning of a new chapter. The decision will provide students, researchers and staff at the University of Hohenheim in Stuttgart with increased opportunities to study, work and collaborate with partner universities across Europe.

The Friends of the German Cancer Research Center (DKFZ) support the DKFZ and aim to help strengthen its position in the international arena. With the DKFZ Innovation Award, presented at this year’s annual reception, the association honors Helmut Salih, a researcher whose innovative work bridges the gap between immunological research and patient care.

The University of Freiburg is strengthening its European collaboration in the field of Artificial Intelligence by having been accepted into the Virtual Centre of Excellence of the European AI initiative ELIAS. The Freiburg researchers contribute their expertise to the European network in areas including machine learning, computer vision, robot learning, automated reasoning, intelligent systems and neurotechnologies, as well as responsible AI.

Robots that can learn and adapt require not only data, AI tools, and algorithms but also direct communication with their users. Jens Kober would like to improve this interaction and as the new head of a research team at Fraunhofer IPA, he is focusing in particular on construction robotics.

In people with severely compromised immune systems, the JC polyomavirus can trigger a currently untreatable, usually fatal brain disease. Now, an international research team looking at the viral capsid has identified binding sites for neutralizing antibodies; these sites could be used to halt infection with JC polyomaviruses.

Prime Vector Technologies GmbH (PVT), a clinical-stage biotechnology company focusing on the development of viral vector-based vaccines, today announced that it has entered into an agreement with Boehringer Ingelheim for the assignment of certain patents and the exclusive licensing of its Orf virus (ORFV) platform for the development of next-generation cancer vaccines.